SciNeuro Pharmaceuticals announced today that it entered into an exclusive licensing agreement with Eli Lilly for antibody therapies. Under the agreement, Shanghai-based SciNeuro obtained an exclusive license to develop and commercialize alpha-synuclein targeted antibodies developed by Lilly within Greater China, which includes mainland China, Hong Kong, Macau and Taiwan, according to a news release. The […]